| Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance L Seguin, JS Desgrosellier, SM Weis, DA Cheresh Trends in cell biology 25 (4), 234-240, 2015 | 810 | 2015 |
| An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition L Seguin, S Kato, A Franovic, MF Camargo, J Lesperance, KC Elliott, ... Nature cell biology 16 (5), 457-468, 2014 | 420 | 2014 |
| Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma E Cosset, S Ilmjärv, V Dutoit, K Elliott, T von Schalscha, MF Camargo, ... Cancer cell 32 (6), 856-868. e5, 2017 | 164 | 2017 |
| Lung adenocarcinoma tumor origin: a guide for personalized medicine L Seguin, M Durandy, CC Feral Cancers 14 (7), 1759, 2022 | 112 | 2022 |
| Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland JS Desgrosellier, J Lesperance, L Seguin, M Gozo, S Kato, A Franovic, ... Developmental cell 30 (3), 295-308, 2014 | 112 | 2014 |
| Galectin-3, a druggable vulnerability for KRAS-addicted cancers L Seguin, MF Camargo, HI Wettersten, S Kato, JS Desgrosellier, ... Cancer discovery 7 (12), 1464-1479, 2017 | 94 | 2017 |
| A MEK-independent role for CRAF in mitosis and tumor progression A Mielgo, L Seguin, M Huang, MF Camargo, S Anand, A Franovic, ... Nature medicine 17 (12), 1641-1645, 2011 | 69 | 2011 |
| A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy L Douguet, S Janho dit Hreich, J Benzaquen, L Seguin, T Juhel, ... Nature Communications 12 (1), 653, 2021 | 64 | 2021 |
| CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase L Seguin, C Liot, R Mzali, R Harada, A Siret, A Nepveu, J Bertoglio Molecular and cellular biology, 2009 | 59 | 2009 |
| Phosphoregulation of MgcRacGAP in mitosis involves Aurora B and Cdk1 protein kinases and the PP2A phosphatase A Touré, R Mzali, C Liot, L Seguin, L Morin, C Crouin, I Chen-Yang, ... FEBS letters 582 (8), 1182-1188, 2008 | 52 | 2008 |
| Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence A Franovic, KC Elliott, L Seguin, MF Camargo, SM Weis, DA Cheresh Cancer research 75 (21), 4466-4473, 2015 | 48 | 2015 |
| Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 SJ Advani, MF Camargo, L Seguin, A Mielgo, S Anand, AM Hicks, ... Nature communications 6 (1), 8154, 2015 | 48 | 2015 |
| APCcdh1 Mediates Degradation of the Oncogenic Rho-GEF Ect2 after Mitosis C Liot, L Seguin, A Siret, C Crouin, S Schmidt, J Bertoglio PloS one 6 (8), e23676, 2011 | 45 | 2011 |
| Regulation of Rho signaling pathways in interleukin‐2‐stimulated human T‐lymphocytes R Mzali, L Seguin, C Liot, A Auger, P Pacaud, G Loirand, C Thibault, ... The FASEB journal 19 (13), 1911-1913, 2005 | 29 | 2005 |
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells L Seguin, S Odouard, F Corlazzoli, SA Haddad, L Moindrot, ... Communications Biology 4 (1), 718, 2021 | 20 | 2021 |
| Dermal fibroblast SLC3A2 deficiency leads to premature aging and loss of epithelial homeostasis FS Tissot, S Estrach, E Boulter, L Cailleteau, L Tosello, L Seguin, ... Journal of Investigative Dermatology 138 (12), 2511-2521, 2018 | 19 | 2018 |
| NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions S Kunz, M Durandy, L Seguin, CC Feral International Journal of Molecular Sciences 24 (17), 13229, 2023 | 11 | 2023 |
| A regulatory circuit controlled by extranuclear and nuclear retinoic acid receptor α determines T cell activation and function A Larange, I Takazawa, K Kakugawa, N Thiault, SM Ngoi, ME Olive, ... Immunity 56 (9), 2054-2069. e10, 2023 | 10 | 2023 |
| Compositions for detecting circulating integrin beta-3 biomarker and methods for detecting cancers and assessing tumor presence or progression, cancer drug resistance and tumor … DA Cheresh, L Seguin, Y Fujita, W Sara US Patent App. 15/568,419, 2018 | 10 | 2018 |
| Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition D Cheresh, L Seguin, S Anand US Patent 9,632,074, 2017 | 10 | 2017 |
